Filtered By:
Condition: Atrial Fibrillation

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 17201 results found since Jan 2013.

Metformin-inclusive Therapy Reduces the Risk of Stroke in Patients with Diabetes: A 4-Year Follow-up Study
Metformin is a kind of oral hypoglycemic agents commonly prescribed to patients with diabetes mellitus. Although past studies had proven its protective effect on cardiovascular risk and related mortality, the evidence of metformin on stroke prevention was still insufficient and conflicting. Our study randomly selected 14,856 patients with diabetes from the database provided by the Taiwan National Health Research Institute, and 2 cohorts were formulated according to whether metformin was in the prescription record. All cases were followed up for 4 years to track their stroke incidence. As a result, 701 (17.5%) of 3999 diabe...
Source: Journal of Stroke and Cerebrovascular Diseases - October 11, 2013 Category: Neurology Authors: Yuan-Yang Cheng, Hsin-Bang Leu, Tzeng-Ji Chen, Chen-Ling Chen, Chia-Hua Kuo, Shin-Da Lee, Chung-Lan Kao Tags: Original Articles Source Type: research

Cryptogenic Stroke with No Cause Demonstrates the Outcome Prediction Utility of TOAST Classifications in a Large Stroke Patient Sample (P1.118)
Conclusion: Even after controlling for higher tPA treatment rates, patients with cryptogenic no cause by TOAST classification had better outcomes than other TOAST groups. Our results suggest that determining stroke etiology with the TOAST classification can be a clinical useful tool for risk stratification for stroke patients even with difficult diagnosis groups like cryptogenic no cause.Disclosure: Dr. Scullen has nothing to disclose. Dr. Monlezun, Jr has nothing to disclose. Dr. George has received research support from Tulane University School of Medicine. Dr. Siegler has nothing to disclose. Dr. Schwickrath has nothing...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Scullen, T., Monlezun, D., George, A., Siegler, J., Schwickrath, M., El Khoury, R., Martin-Schild, S. Tags: Cerebrovascular Disease and Interventional Neurology: Ischemic Stroke Subtype Source Type: research

Cryptogenic Stroke with No Cause Demonstrates the Outcome Prediction Utility of TOAST Classifications in a Large Stroke Patient Sample (I2-1.005)
Conclusion: Even after controlling for higher tPA treatment rates, patients with cryptogenic no cause by TOAST classification had better outcomes than other TOAST groups. Our results suggest that determining stroke etiology with the TOAST classification can be a clinical useful tool for risk stratification for stroke patients even with difficult diagnosis groups like cryptogenic no cause.Disclosure: Dr. Scullen has nothing to disclose. Dr. Monlezun, Jr has nothing to disclose. Dr. George has received research support from Tulane University School of Medicine. Dr. Siegler has nothing to disclose. Dr. Schwickrath has nothing...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Scullen, T., Monlezun, D., George, A., Siegler, J., Schwickrath, M., El Khoury, R., Martin-Schild, S. Tags: New Antithrombotic Agents for Stroke Prevention Poster Presentations Source Type: research

Age Dependence of Risk Factors for Stroke and Death in Young Patients With Atrial Fibrillation: A Nationwide Study Clinical Sciences
Conclusions— The CHA2DS2-VASc score is an applicable tool for all age groups and in nonvalvular atrial fibrillation patients <65 years old, the same risk factors apply.
Source: Stroke - April 28, 2014 Category: Neurology Authors: Melgaard, L., Rasmussen, L. H., Skjoth, F., Lip, G. Y. H., Larsen, T. B. Tags: Acute Cerebral Infarction, Anticoagulants Clinical Sciences Source Type: research

Remote or Extraischemic Intracerebral Hemorrhage--An Uncommon Complication of Stroke Thrombolysis: Results From the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register Clinical Sciences
Conclusions— Differences between risk factor profiles indicate an influence of previous vascular pathology in PHr and acute large-vessel occlusion in PH. Additional research is needed on the effect of pre-existing cerebrovascular disease on complications of recanalization therapy in acute ischemic stroke.
Source: Stroke - May 27, 2014 Category: Neurology Authors: Mazya, M. V., Ahmed, N., Ford, G. A., Hobohm, C., Mikulik, R., Nunes, A. P., Wahlgren, N., Scientific Committee of SITS International, Wahlgren, Davalos, Ford, Grond, Hacke, Hennerici, Kaste, Lees, Roine, Tatlisumak, Toni, Wang, Scientific Committee of Fi Tags: Thrombolysis Clinical Sciences Source Type: research

Abstract 7: Risk of Intracranial Hemorrhage Among Acute Ischemic Stroke Patients Receiving Prior Antiplatelet Therapy and Treated with Intravenous Tissue Plasminogen Activator Session Title: Concurrent I Session B: Oral Abstracts on Stroke Topics
Conclusion: This study represents the largest clinical experience of the safety of thrombolysis in patients on prior antiplatelet therapy. Despite a higher incidence of sICH, the absolute excess risk appears small (0.67%). These findings support current guideline recommendations regarding use of intravenous tPA in patients on antiplatelet therapy with careful weighing of potential risk and benefit.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Xian, Y., Grau-Spulveda, M., Schwamm, L. H., Bhatt, D. L., Smith, E. E., Reeves, M. J., Federspiel, J., Thomas, L., Bettger, J. P., Laskowitz, D. T., Hernandez, A. F., Fonarow, G. C., Peterson, E. D. Tags: Session Title: Concurrent I Session B: Oral Abstracts on Stroke Topics Source Type: research

Association of the ASCO Classification with the Executive Function Subscores of the Montreal Cognitive Assessment in Patients with Postischemic Stroke
Conclusions: These results suggest that the ASCO phenotypic classification of stroke is useful not only for assessing the etiology of ischemic stroke but also for predicting cognitive decline after ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - August 29, 2014 Category: Neurology Authors: Kazuo Washida, Masafumi Ihara, Hisatsugu Tachibana, Kenji Sekiguchi, Hisatomo Kowa, Fumio Kanda, Tatsushi Toda Tags: Original Articles Source Type: research

Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control Clinical Sciences
Conclusions— In Chinese patients with atrial fibrillation, the benefits of warfarin therapy for stroke prevention and ICH risk are closely dependent on the quality of anticoagulation, as reflected by TTR. Even at the top TTR quartile, warfarin was associated with a higher stroke and ICH risk than dabigatran.
Source: Stroke - December 22, 2014 Category: Neurology Authors: Ho, C.-W., Ho, M.-H., Chan, P.-H., Hai, J.-J., Cheung, E., Yeung, C.-Y., Lau, K.-K., Chan, K.-H., Lau, C.-P., Lip, G. Y. H., Leung, G. K.-K., Tse, H.-F., Siu, C.-W. Tags: Coumarins, Other anticoagulants, Anticoagulants Clinical Sciences Source Type: research

Changes in Functional Outcome Over the First Year After Stroke: An Observational Study From the Swedish Stroke Register Clinical Sciences
Conclusions— Transition from ADL independence to dependence was observed in a high proportion of patients between 3 and 12 months, challenging the common belief that functioning after stroke is stable beyond 3 months. Deterioration occurred more commonly in women, among whom 1/6 converted to dependency.
Source: Stroke - January 26, 2015 Category: Neurology Authors: Ullberg, T., Zia, E., Petersson, J., Norrving, B. Tags: Acute Cerebral Infarction Clinical Sciences Source Type: research

Elevated VLDL is associated with cardioembolic stroke and improved functional outcome in patients with acute ischemic stroke (P3.074)
CONCLUSIONS: The relationship between cardioembolic stroke and poor short-term outcomes likely underlies the association between vLDL and outcomes in our population. Further research is warranted to investigate the impact of vLDL in stroke etiology and patient outcomes.Disclosure: Dr. George has nothing to disclose. Dr. Monlezun, Jr has nothing to disclose. Dr. Samai has nothing to disclose. Dr. Waring has nothing to disclose. Dr. Dowell has nothing to disclose. Dr. Valmoria has nothing to disclose. Dr. Martin-Schild has received personal compensation for activities with Genentech as a speakers bureau participant.
Source: Neurology - April 8, 2015 Category: Neurology Authors: George, A., Monlezun, Jr, D., Samai, A., Waring, E., Dowell, L., Valmoria, M., Martin-Schild, S. Tags: Cerebrovascular Disease and Interventional Neurology: Ischemic Stroke Outcome Source Type: research

Routine troponin measurements are unnecessary in acute ischemic stroke evaluations (P4.285)
CONCLUSIONS: Troponin elevation in patients with ischemic stroke is not caused by acute myocardial ischemia unless iatrogenic in the setting of vasopressor administration. Serum troponins should be measured based on clinical context rather than routinely in all acute ischemic stroke patients.Disclosure: Dr. Ali has nothing to disclose. Dr. Young has nothing to disclose. Dr. Rabinstein has received royalty payments from Elsevier and Oxford University Press. Dr. Rabinstein has received research support from DJO Global. Dr. Flemming has nothing to disclose. Dr. Fugate has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Ali, F., Young, J., Rabinstein, A., Flemming, K., Fugate, J. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Ischemic Stroke Care Source Type: research

Elevated Cardiac Troponin-T in acute ischemic stroke (P4.286)
CONCLUSIONS:Elevated cardiac troponin T level after acute ischemic stroke is frequently seen and suggests likely to present of potential cardiac sources of embolism. However, there is no correlation with specific sources. Study Supported by:Disclosure: Dr. Kim has nothing to disclose. Dr. Kim has nothing to disclose. Dr. Lee has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Kim, H.-k., Kim, J. H., Lee, K.-Y. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Ischemic Stroke Care Source Type: research

Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin
Commentary on: Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med 2014;127:1172–8 . Context Randomised trials have shown that patients with atrial fibrillation (AF) who are treated with a non-vitamin K antagonist oral anticoagulant (NOAC), compared with warfarin, have similar or lower rates of stroke and major bleeding, markedly reduced rates of intracranial bleeding and a consistent pattern of reduced mortality.1 Dabigatran 150 mg two times a day is the only NOAC that can significantly...
Source: Evidence-Based Medicine - May 22, 2015 Category: Internal Medicine Authors: Eikelboom, J. W., Bosch, J. Tags: Epidemiologic studies, Time-to-event methods, Drugs: cardiovascular system, Stroke, Arrhythmias Aetiology/Harm Source Type: research

Unfavorable Outcome of Thrombolysis in Chinese Patients with Cardioembolic Stroke: a Prospective Cohort Study.
CONCLUSIONS: Patients with cardioembolic stroke had more SICH after thrombolysis, and worse clinical outcome at 3-month follow-up compared with those with LAA. This emphasizes the importance of preventing cardioembolism. PMID: 26096605 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - June 20, 2015 Category: Neuroscience Authors: Wang XG, Zhang LQ, Liao XL, Pan YS, Shi YZ, Wang CJ, Wang YL, Liu LP, Zhao XQ, Wang YJ, Li D, Wang CX, Thrombolysis Implementation and Monitoring of acute ischemic Stroke in China (TIMS-China) Investigators Tags: CNS Neurosci Ther Source Type: research

Socioeconomic Inequalities in the Prescription of Oral Anticoagulants in Stroke Patients With Atrial Fibrillation Clinical Sciences
Conclusion— Differences by age, income, education, and country of birth were found in the prescribing of OACs after stroke. Differences were not explained by common risk factors. This indicates socioeconomic inequalities in the prescribing of preventive treatment after stroke.
Source: Stroke - July 27, 2015 Category: Neurology Authors: Sjolander, M., Eriksson, M., Asplund, K., Norrving, B., Glader, E.-L. Tags: Secondary prevention, Anticoagulants Clinical Sciences Source Type: research